Frontiers in Nutrition (Feb 2023)
The combination of hand grip strength and modified Glasgow prognostic score predicts clinical outcomes in patients with liver cancer
- Yue Chen,
- Yue Chen,
- Guo-Tian Ruan,
- Guo-Tian Ruan,
- Jin-Yu Shi,
- Jin-Yu Shi,
- Tong Liu,
- Tong Liu,
- Chen-An Liu,
- Chen-An Liu,
- Hai-Lun Xie,
- Hai-Lun Xie,
- Meng-Meng Song,
- Meng-Meng Song,
- Zi-Wen Wang,
- Zi-Wen Wang,
- Chun-Lei Hu,
- Chun-Lei Hu,
- He-Yang Zhang,
- He-Yang Zhang,
- Xiao-Wei Zhang,
- Xiao-Wei Zhang,
- Hai-Ying Tian,
- Hai-Ying Tian,
- Yi-Zhong Ge,
- Yi-Zhong Ge,
- Ming Yang,
- Ming Yang,
- Yu-Ying Liu,
- Yu-Ying Liu,
- Shi-Qi Lin,
- Shi-Qi Lin,
- Xiao-Yue Liu,
- Xiao-Yue Liu,
- Xin Zheng,
- Xin Zheng,
- Kun-Hua Wang,
- Kun-Hua Wang,
- Ming-Hua Cong,
- Xian Shen,
- Xin Wang,
- Xin Wang,
- Li Deng,
- Li Deng,
- Han-Ping Shi,
- Han-Ping Shi
Affiliations
- Yue Chen
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Yue Chen
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Guo-Tian Ruan
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Guo-Tian Ruan
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Jin-Yu Shi
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Jin-Yu Shi
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Tong Liu
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Tong Liu
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Chen-An Liu
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Chen-An Liu
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Hai-Lun Xie
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Hai-Lun Xie
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Meng-Meng Song
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Meng-Meng Song
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Zi-Wen Wang
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Zi-Wen Wang
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Chun-Lei Hu
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Chun-Lei Hu
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- He-Yang Zhang
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- He-Yang Zhang
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Xiao-Wei Zhang
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Xiao-Wei Zhang
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Hai-Ying Tian
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Hai-Ying Tian
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Yi-Zhong Ge
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Yi-Zhong Ge
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Ming Yang
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Ming Yang
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Yu-Ying Liu
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Yu-Ying Liu
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Shi-Qi Lin
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Shi-Qi Lin
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Xiao-Yue Liu
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Xiao-Yue Liu
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Xin Zheng
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Xin Zheng
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Kun-Hua Wang
- Clinical Medical College, Yunnan University, Kunming, China
- Kun-Hua Wang
- General Surgery Clinical Medical Center of Yunnan Province, Kunming, China
- Ming-Hua Cong
- Comprehensive Oncology Department, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Xian Shen
- The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
- Xin Wang
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Xin Wang
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Li Deng
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Li Deng
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- Han-Ping Shi
- Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China
- Han-Ping Shi
- Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China
- DOI
- https://doi.org/10.3389/fnut.2023.1062117
- Journal volume & issue
-
Vol. 10
Abstract
PurposePrevious studies have shown that both hand grip strength (HGS) and the modified Glasgow Prognostic Score (mGPS) are associated with poor clinical outcomes in patients with liver cancer. In spite of this, no relevant studies have been conducted to determine whether the combination of HGS and mGPS can predict the prognosis of patients with liver cancer. Accordingly, this study sought to explore this possibility.MethodsThis was a multicenter study of patients with liver cancer. Based on the optimal HGS cutoff value for each sex, we determined the HGS cutoff values. The patients were divided into high and low HGS groups based on their HGS scores. An mGPS of 0 was defined as low mGPS, whereas scores higher than 0 were defined as high mGPS. The patients were combined into HGS-mGPS groups for the prediction of survival. Survival analysis was performed using Kaplan–Meier curves. A Cox regression model was designed and adjusted for confounders. To evaluate the nomogram model, receiver operating characteristic curves and calibration curves were used.ResultsA total of 504 patients were enrolled in this study. Of these, 386 (76.6%) were men (mean [SD] age, 56.63 [12.06] years). Multivariate analysis revealed that patients with low HGS and high mGPS had a higher risk of death than those with neither low HGS nor high mGPS (hazard ratio [HR],1.50; 95% confidence interval [CI],1.14–1.98; p = 0.001 and HR, 1.55; 95% CI, 1.14–2.12, p = 0.001 respectively). Patients with both low HGS and high mGPS had 2.35-fold increased risk of death (HR, 2.35; 95% CI, 1.52–3.63; p < 0.001). The area under the curve of HGS-mGPS was 0.623. The calibration curve demonstrated the validity of the HGS-mGPS nomogram model for predicting the survival of patients with liver cancer.ConclusionA combination of low HGS and high mGPS is associated with poor prognosis in patients with liver cancer. The combination of HGS and mGPS can predict the prognosis of liver cancer more accurately than HGS or mGPS alone. The nomogram model developed in this study can effectively predict the survival outcomes of liver cancer.
Keywords